Navigation Links
mecA ASR

ProductsmecA ASR
Company Cepheid
Item mecA ASR
Features 
Description The mecA ASR contains primers and a FAM-labeled probe that is designed to detect a 146 bp region of the mecA gene. In addition, this ASR contains primers, a Texas Red-labeled probe and DNA for an internal control sequence. This ASR requires an instrument that can detect FAM and Texas Red reporter dyes such as the Cepheid SmartCycler System.

The Cepheid Analyte Specific Reagent* (ASR) program is comprised of a series of easy-to-use primer and probe sets in a convenient lyophilized bead format. Every ASR product is manufactured under cGMP for maximum product consistency and quality. Cepheid ASRs are also delivered with an internal control** to ensure optimum reliability by confirming that negatives are truly negative not inhibited. Each ASR product is designed for rapid results on real-time PCR instruments like the Cepheid SmartCycler System.

* Analytical and performance characteristics are not established. ASRs can only be sold to clinical laboratories regulated under the CLIA of 1988, as qualified to perform high complexity testing under 42 CFR part 493 or under VHA directive 1106.
** See specific ASR product datasheet for internal control information.

Info Cepheid
Customer Service: (408) 541-4191
Web site: http://www.cepheid.com/

Related medicine products :

1. M.R.I. Vital Port Systems (standard size)
2. Titanium Vital Port Systems (standard size)
3. Petite Titanium Vital Port Systems
4. Petite M.R.I. Vital Port Systems
5. Mini Titanium Vital Port Systems
6. Dual Chamber M.R.I. Vital Port Systems
7. Dual Chamber Titanium Vital Port Systems
8. Petite Dual Chamber Titanium Vital Port Systems
9. Mini Titanium Vital-Port Systems for Peripheral Placement
10. Vitality DS
11. Vitality DS VR
TAG: mecA ASR
...m DePuy offers a comprehensive combination of comf...commendations regarding occupational exposure to b...d for comfort. , ,The Nighthawk, a new additio...personal protection system for the healthcare prof...
Ideal for sensory nerve testing, Cadwells finger clip electrodes are constructed of solid, surgical-grade stainless steel and come with color-coded handles and ultra-flexible, red-and-black twisted p
Cadwells stainless steel ring electrodes feature a molded grip for convenient handling and an adjustable slider that moves smoothly and locks firmly in one motion. Cadwell rings also feature ultrafle
Silver/silver chloride ground has a large surface area for superb patient grounding. For use with minicrocodile clip lead wires. Dimensions: 4.5 cm (1.75 in) long, 3.1 cm (1.25 in) wide. Each 100-cou
Medicine Products:
(Date:11/21/2008)...fresh from basic training and now serving overseas...fe he saved by donating his rare blood type. , ... Korea (PRWEB) November 21, 2008 -- A local Korean...on saved her life, met for the first time when she...Airman Tamarias Pope, 8th Security Forces Squadron...
(Date:11/21/2008)...eld on January 8, 2009 , , TORONTO, Nov. 21...Inc. ("MedEmerg") (OTCBB: MDER), one of Canada,s l...ay that it has obtained an interim order from the ...reviously announced plan of arrangement (the "Arra...("AIM") will acquire all of MedEmerg,s outstanding...
(Date:11/21/2008)...rstCall/ -- Heska Corporation,(Nasdaq: HSKA ) t...iety of,Security Analysts, 12th Annual Biotech an... at 1177 Avenue of the Americas, 2nd Floor in New ...at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain Tim...two weeks,following the presentation through a li...
(Date:11/21/2008)...gainst Lennox-Gastaut syndrome , , FRIDA...anzel (rufinamide) has been approved as a suppleme...ed Lennox-Gastaut syndrome, the U.S. Food and Drug...l was based on results of a four-month clinical tr...to patients who took a placebo, those who took the...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...stitute had discovered a new molecular explanation...ed behavior in the disease called porphyria, the d...king George III. The Dana-Farber scientists say i...e August 26 issue of the journal Cell that the nut...
...ought of as a as paranormal phenomena, may in fact...ience their own bodies. Despite the high incidence...nown about the phenomenon. Around 10% of the popul...OBE) at some time, typically involving a sensation...
...colloborate with Nobex Corporation of United State...cular diseases. The spokesperson of Biocon informe...ollaboration // on Tuesday for development of pept...ar diseases. The Biocon press release said, “The c...
... September issue of the Harvard Health Letter, fro... that advocate quick and short working out session...ealth conditions that can lead to diseases. To pre... longer and strenuous workout sessions are require...
Other Medicine News:Health News:Study Unveils New Insight To The Madness Of King George III 2
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
(Date:11/19/2008)...m Roche- , , MONTVALE, N.J., Nov. 19 /PRNew...Nasdaq: MEMY ) today announced that it has achie...3487/MEM 3454, its lead alpha-7 nicotinic receptor...schizophrenia (CIAS). The Company has randomized ....0 million payment from its partner Roche. Memory...
(Date:11/18/2008)...ire-USNewswire/ -- Forty-two leading U. S. scienti...l forum to consider cutting-edge innovations that ...onomy from outbreaks of dangerous zoonotic disease...ng those innovations: , , , , A...at detects highly contagious and dangerous zoonoti...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Nature study demonstrates that bacterial clotting depends on clustering 5691 1Nature study demonstrates that bacterial clotting depends on clustering 5691 2Excess Weight Seems to Boost Breast Cancer Risk 28489 1Excess Weight Seems to Boost Breast Cancer Risk 28489 2Excess Weight Seems to Boost Breast Cancer Risk 28489 3Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 1Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 1Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 10
...h VELCADE, lenalidomide,and dexamethasone , ,KOS, ...um,Pharmaceuticals, Inc. (Nasdaq: MLNM) today repo...ical trials of VELCADE based,therapies that showed... / complete response(1) (CR) rates in newly diagno...e presented at the,prestigious 11th International ...
..., 2007 - The drug most,commonly used to arrest pre... another common treatment to cause mild to serious...udy from researchers at,Lucile Packard Children,s ...e. Their findings suggest that, since the effectiv... should consider side,effects more strongly when c...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 2Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 3Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 4